A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM

NCT04967690 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Glioblastoma

Interventions

DRUG: SI-053

Sponsor

Double Bond Pharmaceutical AB